☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
83-0982969
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification Number)
|
200 Clarendon Street
Boston, Massachusetts
|
02116
|
|
(Address of principal executive offices)
|
(Zip code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
Common Stock, par value $0.0001 per share
|
ADN
|
The Nasdaq Global Market
|
||
Warrants
|
ADNWW
|
The Nasdaq Global Market
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
Non-accelerated filer
|
☒
|
Smaller reporting company
|
☒
|
Emerging growth company
|
☒
|
• |
our ability to maintain the listing of our shares of common stock and warrants on Nasdaq;
|
• |
our ability to raise financing in the future;
|
• |
our success in retaining or recruiting officers, key employees or directors;
|
• |
factors relating to our business, operations and financial performance, including:
|
o |
our ability to control the costs associated with our operations;
|
o |
our ability to grow and manage growth profitably;
|
o |
our reliance on complex machinery for our operations and production;
|
o |
the market’s willingness to adopt our technology;
|
o |
our ability to maintain relationships with customers;
|
o |
the potential impact of product recalls;
|
o |
our ability to compete within our industry;
|
o |
increases in costs, disruption of supply or shortage of raw materials;
|
o |
risks associated with strategic alliances or acquisitions, including the acquisition of SerEnergy A/S, a Danish stock corporation (“SerEnergy”) and fischer eco solutions GmbH, a German limited liability company (“FES”),
former wholly-owned subsidiaries of F.E.R. fischer Edelstahlrohre GmbH, completed on August 31, 2021;
|
o |
the impact of unfavorable changes in U.S. and international regulations;
|
o |
the availability of and our ability to meet the terms and conditions for government grants and economic incentives; and
|
o |
our ability to protect our intellectual property rights;
|
• |
market conditions and global and economic factors beyond our control, including the potential adverse effects of the ongoing global coronavirus (COVID-19) pandemic on capital markets, general economic conditions, unemployment
and our liquidity, operations and personnel;
|
• |
volatility of our stock price and potential share dilution; and
|
• |
future exchange and interest rates.
|
Page
|
||
PART I—FINANCIAL INFORMATION
|
||
Item 1.
|
Unaudited Condensed Consolidated Financial Statements
|
3 |
Unaudited Condensed Consolidated Balance Sheets
|
3 | |
Unaudited Condensed Consolidated Statements of Operations
|
4 | |
Unaudited Condensed Consolidated Statements of Comprehensive Income / (Loss)
|
5
|
|
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity / (Deficit)
|
6 | |
Unaudited Condensed Consolidated Statements of Cash Flows
|
10
|
|
Notes to Unaudited Condensed Consolidated Financial Statements
|
11
|
|
Item 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
28
|
Item 3.
|
Quantitative and Qualitative Disclosures About Market Risk
|
46
|
Item 4.
|
Controls and Procedures
|
47
|
PART II—OTHER INFORMATION
|
||
Item 1.
|
Legal Proceedings
|
49
|
Item 1A.
|
Risk Factors
|
49 |
Item 2.
|
Unregistered Sales of Equity Securities and Use of Proceeds
|
49
|
Item 3.
|
Exhibits
|
50
|
Signatures
|
51 |
As of |
||||||||
ASSETS
|
September 30, 2021
(Unaudited)
|
December 31,
2020
|
||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
92,492,367
|
$
|
515,734
|
||||
Accounts receivable
|
5,569,801
|
421,059
|
||||||
Due from related parties
|
-
|
67,781
|
||||||
Contract assets
|
936,259
|
85,930
|
||||||
Inventories
|
5,598,574
|
107,939
|
||||||
Prepaid expenses and Other current assets
|
3,767,096
|
496,745
|
||||||
Total current assets
|
108,364,097
|
1,695,188
|
||||||
Non-current assets: |
||||||||
Goodwill and intangibles, net
|
54,281,798
|
-
|
||||||
Property and equipment, net
|
7,883,042
|
198,737
|
||||||
Other non-current assets
|
2,155,156 | 136 | ||||||
Deferred tax assets
|
1,279,969 |
- |
||||||
Total non-current assets | 65,599,965 | 198,873 | ||||||
Total assets
|
$
|
173,964,062
|
$
|
1,894,061
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT)
|
||||||||
Current liabilities:
|
||||||||
Trade and other payables
|
$
|
5,522,624
|
$
|
881,394
|
||||
Due to related parties
|
30,000
|
1,114,659
|
||||||
Deferred income from grants, current
|
1,098,019
|
158,819
|
||||||
Contract liabilities
|
28,832
|
167,761
|
||||||
Other current liabilities
|
7,595,619
|
904,379
|
||||||
Income tax payable
|
1,135,199
|
201,780
|
||||||
Total current liabilities
|
15,410,293
|
3,428,792
|
||||||
Non-current liabilities: | ||||||||
Warrant liability
|
17,282,987
|
-
|
||||||
Deferred tax liabilities
|
3,756,859 | - |
||||||
Deferred income from grants, non-current
|
171,995
|
182,273
|
||||||
Other long-term liabilities
|
1,209,336
|
76,469
|
||||||
Total non-current liabilities | 22,421,177 | 258,742 | ||||||
Total liabilities
|
37,831,470
|
3,687,534
|
||||||
Commitments and contingent liabilities
|
-
|
-
|
||||||
Stockholders’ equity / (deficit)
|
||||||||
Common stock ($0.0001 par value per share; Shares authorized: 110,000,000 at September 30, 2021 and December 31, 2020; Issued and outstanding: 51,253,591 and 25,033,398 at September
30, 2021 and December 31, 2020, respectively)
|
5,125
|
2,503
|
||||||
Preferred stock ($0.0001 par value per share; Shares authorized: 1,000,000 at September 30, 2021 and December 31, 2020; nil issued and outstanding at September 30, 2021 and December
31, 2020
|
-
|
-
|
||||||
Additional paid-in capital
|
161,263,673
|
10,993,762
|
||||||
Accumulated other comprehensive (loss) / income
|
(717,328
|
)
|
111,780
|
|||||
Accumulated deficit
|
(24,418,878
|
)
|
(12,901,518
|
)
|
||||
Total stockholders’ equity / (deficit)
|
136,132,592
|
(1,793,473
|
)
|
|||||
Total liabilities and stockholders’ equity / (deficit)
|
$
|
173,964,062
|
$
|
1,894,061
|
|
Three months ended September 30,
(Unaudited)
|
Nine months ended September 30,
(Unaudited)
|
||||||||||||||
|
2021
|
2020
|
2021 |
2020 |
||||||||||||
Revenue, net
|
$
|
1,673,998
|
$
|
225,412
|
$ | 4,166,754 | $ | 526,032 | ||||||||
Cost of revenues
|
(1,645,781
|
)
|
(90,477
|
)
|
(2,662,476 | ) | (374,430 | ) | ||||||||
Gross profit
|
28,217
|
134,934
|
1,504,278 | 151,602 | ||||||||||||
Income from grants
|
507,606
|
16,076
|
631,787 | 159,182 | ||||||||||||
Research and development expenses
|
(893,215
|
)
|
(37,640
|
)
|
(1,561,049 | ) | (81,273 | ) | ||||||||
Administrative and selling expenses
|
(13,040,649
|
)
|
(886,629
|
)
|
(27,558,242 | ) | (1,641,063 | ) | ||||||||
Amortization of intangibles
|
(309,734
|
)
|
-
|
(467,447 | ) | - | ||||||||||
Operating loss
|
(13,707,773
|
)
|
(773,258
|
)
|
(27,450,673 | ) | (1,411,552 | ) | ||||||||
Finance costs
|
(13,542
|
)
|
(1,712
|
)
|
(26,961 | ) | (4,749 | ) | ||||||||
Fair value change of warrant liability
|
2,421,874
|
-
|
15,833,334 | - | ||||||||||||
Foreign exchange differences, net
|
(15,256
|
)
|
(8,005
|
)
|
(2,141 | ) | (26,584 | ) | ||||||||
Other (expenses) / income, net
|
(15,960
|
)
|
31,058
|
78,146 | 24,848 | |||||||||||
Loss before income tax
|
(11,330,657
|
)
|
(751,917
|
)
|
(11,568,295 | ) | (1,418,037 | ) | ||||||||
Income tax
|
50,935
|
3,101
|
50,935 | - | ||||||||||||
Net loss
|
$
|
(11,279,722
|
)
|
$
|
(748,816
|
)
|
$ | (11,517,360 | ) | $ | (1,418,037 | ) | ||||
Net loss per share |
||||||||||||||||
Basic loss per share
|
(0.23
|
)
|
(0.03
|
)
|
(0.26 | ) | (0.07 | ) | ||||||||
Basic weighted average number of shares
|
48,325,164
|
23,182,817 | 43,982,039 | 21,180,639 | ||||||||||||
Diluted loss per share
|
(0.23
|
)
|
(0.03
|
)
|
(0.26 | ) | (0.07 | ) | ||||||||
Diluted weighted average number of shares
|
48,325,164
|
23,182,817
|
43,982,039 | 21,180,639 |
Three months ended September 30,
(Unaudited)
|
Nine months ended September 30,
(Unaudited)
|
|||||||||||||||
2021
|
2020
|
2021 | 2020 |
|||||||||||||
Net loss
|
$ | (11,279,722 | ) | $ | (748,816 | ) | $ | (11,517,360 | ) | $ | (1,418,037 | ) | ||||
Other comprehensive income / (loss), net of tax effect:
|
||||||||||||||||
Foreign currency translation adjustment
|
(540,871
|
)
|
(2,042
|
)
|
(829,108 | ) | (13,544 | ) | ||||||||
Total other comprehensive loss
|
(540,871
|
)
|
(2,042
|
)
|
(829,108 | ) | (13,544 | ) | ||||||||
Comprehensive loss
|
$
|
(11,820,594
|
)
|
$
|
(750,858
|
)
|
$ | (12,346,468 | ) | $ | (1,431,581 | ) |
Three Months Ended September 30, 2021
|
||||||||||||||||||||||||||||||||||||||||
Preferred
Stock Series A Shares |
Amount
|
Preferred Stock
Series Seed Shares |
Amount
|
Common Stock
Shares |
Amount
|
Additional Paid-in
Capital |
Accumulated
Deficit |
Accumulated
OCI |
Total Stockholders'
(Deficit) Equity |
|||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
Balance as of June 30, 2021 (Unaudited)
|
-
|
$
|
-
|
-
|
$
|
-
|
46,128,745
|
$
|
4,613
|
$
|
119,964,708
|
$
|
(13,139,155
|
)
|
$
|
(176,457
|
)
|
$
|
106,653,709
|
|||||||||||||||||||||
Share capital increase (Unaudited)
|
-
|
-
|
-
|
-
|
5,124,846
|
512
|
37,923,348
|
-
|
-
|
37,923,860
|
||||||||||||||||||||||||||||||
Stock based compensation expense (Unaudited)
|
-
|
-
|
-
|
-
|
-
|
-
|
3,375,616
|
-
|
-
|
3,375,616
|
||||||||||||||||||||||||||||||
Net loss (Unaudited)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(11,279,722
|
)
|
-
|
(11,279,722
|
)
|
||||||||||||||||||||||||||||
Other comprehensive loss (Unaudited)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(540,871
|
)
|
(540,871
|
)
|
||||||||||||||||||||||||||||
Balance as of September 30, 2021 (Unaudited)
|
-
|
$
|
-
|
-
|
$
|
-
|
51,253,591
|
$
|
5,125
|
$
|
161,263,673
|
$
|
(24,418,878
|
)
|
$
|
(717,328
|
)
|
$
|
136,132,592
|
Nine Months Ended September 30, 2021 | ||||||||||||||||||||||||||||||||||||||||
Preferred
Stock
Series A Shares
|
Amount
|
Preferred
Stock
Series Seed
Shares
|
Amount
|
Common
Stock
Shares
|
Amount
|
Additional Paid-in
Capital
|
Accumulated
Deficit
|
Accumulated
OCI
|
Total Stockholders'
(Deficit) Equity
|
|||||||||||||||||||||||||||||||
Balance as of December 31, 2020
|
844,037
|
$
|
845
|
2,095,592
|
$
|
2,096
|
3,017,057
|
$
|
3,017
|
$
|
10,990,307
|
$
|
(12,901,518
|
)
|
$
|
111,780
|
$
|
(1,793,473
|
)
|
|||||||||||||||||||||
Retroactive application of recapitalization (Unaudited)
|
(844,037
|
)
|
(845
|
)
|
(2,095,592
|
)
|
(2,096
|
)
|
22,016,341
|
(514
|
)
|
3,455
|
-
|
-
|
-
|
|||||||||||||||||||||||||
Adjusted balance, beginning of period (Unaudited)
|
-
|
-
|
-
|
-
|
25,033,398
|
2,503
|
10,993,762
|
(12,901,518
|
)
|
111,780
|
(1,793,473
|
)
|
||||||||||||||||||||||||||||
Business combination and PIPE financing (Unaudited)
|
-
|
-
|
-
|
-
|
21,072,549
|
2,107
|
108,005,876
|
-
|
-
|
108,007,984
|
||||||||||||||||||||||||||||||
Share capital increase from warrants exercise (Unaudited) |
- | - | - | - | 22,798 | 2 | 262,175 | - | - | 262,177 | ||||||||||||||||||||||||||||||
Share capital increase (Unaudited) |
- |
- |
- |
- |
5,124,846 |
512 |
37,923,348 |
- |
- |
37,923,860 |
||||||||||||||||||||||||||||||
Stock based compensation expense (Unaudited) |
- | - | - | - | - | - | 4,078,513 | - | - | 4,078,513 | ||||||||||||||||||||||||||||||
Net loss (Unaudited)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(11,517,360
|
)
|
-
|
(11,517,360
|
)
|
||||||||||||||||||||||||||||
Other comprehensive loss (Unaudited) |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(829,108
|
)
|
(829,108
|
)
|
||||||||||||||||||||||||||||
Balance as of September 30, 2021 (Unaudited)
|
-
|
$
|
-
|
-
|
$
|
-
|
51,253,591
|
$
|
5,125
|
$
|
161,263,673
|
$
|
(24,418,878
|
)
|
$
|
(717,328
|
)
|
$
|
136,132,592
|
Three Months Ended September 30, 2020 | ||||||||||||||||||||||||||||||||||||||||
Preferred
Stock Series A Shares |
Amount
|
Preferred Stock
Series Seed Shares |
Amount
|
Common Stock
Shares |
Amount
|
Additional Paid-in
Capital |
Accumulated
Deficit |
Accumulated
OCI |
Total Stockholders'
(Deficit) Equity |
|||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
Balance as of June 30, 2020 (Unaudited)
|
-
|
$
|
-
|
-
|
$
|
-
|
21,332,235
|
$
|
2,133
|
$
|
10,314,200
|
$
|
(10,436,840
|
)
|
$
|
107,357
|
$
|
(13,150
|
)
|
|||||||||||||||||||||
Issuance of non-vested stock awards* (Unaudited)
|
-
|
-
|
-
|
-
|
3,755,010
|
376
|
8,559
|
-
|
-
|
8,935
|
||||||||||||||||||||||||||||||
Repurchase of shares* (Unaudited)
|
-
|
-
|
-
|
-
|
(53,848
|
)
|
(5
|
)
|
(21,730
|
)
|
(12,857
|
)
|
-
|
(34,593
|
)
|
|||||||||||||||||||||||||
Recognition of stock grant plan (Unaudited)
|
-
|
-
|
-
|
-
|
-
|
-
|
236,628
|
-
|
-
|
236,628
|
||||||||||||||||||||||||||||||
Net loss (Unaudited)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(748,816
|
)
|
-
|
(748,816
|
)
|
||||||||||||||||||||||||||||
Other comprehensive loss (Unaudited)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(2,042
|
)
|
(2,042
|
)
|
||||||||||||||||||||||||||||
Balance as of September 30, 2020 (Unaudited)
|
-
|
$
|
-
|
-
|
$
|
-
|
25,033,398
|
$
|
2,503
|
$
|
10,537,657
|
$
|
(11,198,513
|
)
|
$
|
105,315
|
$
|
(553,039
|
)
|
Nine Months Ended September 30, 2020 | ||||||||||||||||||||||||||||||||||||||||
Preferred Stock
Series A Shares
|
Amount
|
Preferred
Stock
Series Seed
Shares
|
Amount
|
Common
Stock
Shares
|
Amount
|
Additional
Paid-in
Capital
|
Accumulated
Deficit |
Accumulated
OCI |
Total
Stockholders' (Deficit)
Equity
|
|||||||||||||||||||||||||||||||
Balance as of December 31, 2019
|
314,505
|
$
|
315
|
2,108,405
|
$
|
2,108
|
888,184
|
$
|
888
|
$
|
8,811,647
|
$
|
(9,767,619
|
)
|
$
|
118,859
|
$
|
(833,802
|
)
|
|||||||||||||||||||||
Retroactive application of recapitalization (Unaudited)
|
(314,505
|
)
|
(315
|
)
|
(2,108,405
|
)
|
(2,108
|
)
|
13,026,925
|
503 |
1,920
|
-
|
-
|
-
|
||||||||||||||||||||||||||
Adjusted balance, beginning of period (Unaudited)
|
-
|
-
|
-
|
-
|
13,915,109
|
1,392
|
8,813,567
|
(9,767,619
|
)
|
118,859
|
(833,802
|
)
|
||||||||||||||||||||||||||||
Issuance of preferred stock* (Unaudited)
|
-
|
-
|
-
|
-
|
2,225,396
|
223 |
1,429,782
|
-
|
-
|
1,430,005
|
||||||||||||||||||||||||||||||
Issuance of non-vested stock awards* (Unaudited) | - | - | - | - | 9,135,138 | 914 | 20,822 | - | - | 21,736 | ||||||||||||||||||||||||||||||
Repurchase of shares* (Unaudited) |
- | - | - | - | (242,245 | ) | (24 | ) | (139,910 | ) | (12,857 | ) | - | (152,792 | ) | |||||||||||||||||||||||||
Recognition of stock grant plan (Unaudited) |
- | - | - | - | - | - | 413,396 | - | - | 413,396 | ||||||||||||||||||||||||||||||
Net loss (Unaudited)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(1,418,037
|
)
|
- |
(1,418,037
|
)
|
||||||||||||||||||||||||||||
Other comprehensive loss (Unaudited)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(13,544
|
)
|
(13,544
|
)
|
||||||||||||||||||||||||||||
Balance as of September 30, 2020 (Unaudited)
|
-
|
$
|
-
|
-
|
$
|
-
|
25,033,398
|
$
|
2,503
|
$
|
10,537,657
|
$
|
(11,198,513
|
)
|
$
|
105,315
|
$
|
(553,039
|
)
|
*
|
The amounts have been retroactively restated to give effect to the recapitalization transaction. |
Nine months ended September 30,
(Unaudited)
|
||||||||
2021
|
2020
|
|||||||
Net Cash used in Operating Activities
|
$
|
(24,690,329
|
)
|
$
|
(1,045,004
|
)
|
||
Cash Flows from Investing Activities:
|
||||||||
Purchases of property and equipment
|
(2,658,584
|
)
|
(89,123
|
)
|
||||
Advances for the acquisition of property and equipment |
(1,917,856 | ) | - | |||||
Acquisition of subsidiaries, net of cash acquired
|
(19,425,378
|
)
|
-
|
|||||
Net Cash used in Investing Activities
|
$
|
(24,001,818
|
)
|
$
|
(89,123
|
)
|
||
Cash Flows from Financing Activities:
|
||||||||
Business Combination and PIPE financing, net of issuance costs paid
|
141,120,851
|
-
|
||||||
Proceeds of issuance of preferred stock
|
-
|
1,430,005
|
||||||
Proceeds from issuance of non-vested stock awards |
- | 21,736 | ||||||
Repurchase of shares |
- | (69,430 | ) | |||||
Proceeds of issuance of common stock and paid-in capital from warrants exercise |
262,177 | - | ||||||
State loan proceeds |
113,377 | - | ||||||
Repayment of convertible promissory notes
|
-
|
(500,000
|
)
|
|||||
Net Cash provided by Financing Activities
|
$
|
141,496,405
|
$
|
882,311
|
||||
Net increase / (decrease) in cash and cash equivalents
|
$
|
92,804,258
|
$
|
(251,815
|
)
|
|||
Effect of exchange rate changes on cash and cash equivalents
|
(827,624
|
)
|
(17,918
|
)
|
||||
Cash and cash equivalents at the beginning of the period
|
515,734
|
1,199,015
|
||||||
Cash and cash equivalents at the end of the period
|
$ |
92,492,367
|
$
|
929,283
|
||||
Supplemental Cash Flow Information | ||||||||
Non-cash Operating Activities: | ||||||||
Recognition of stock grant plan | $ | 4,078,513 | $ | 413,396 |
1. |
Basis of presentation
|
(a) |
Overview
|
(b) |
Unaudited Condensed Consolidated Financial Statements
|
(c)
|
Going Concern
|
2. |
Summary of Significant Accounting Policies:
|
(a)
|
Business
acquisitions, Goodwill and Intangible Assets
|
(b) |
Warrants
|
(c) |
Fair Value of Financial Instruments
|
Warrant Liability
|
||||
Estimated fair value at February 4, 2021
|
$
|
33,116,321
|
||
Change in estimated fair value
|
$
|
(15,833,334
|
)
|
|
Estimated fair value at September 30, 2021
|
$
|
17,282,987
|
Stock price
|
$
|
8.70
|
||
Exercise price (strike price)
|
$
|
11.50
|
||
Risk-free interest rate
|
0.83
|
%
|
||
Volatility
|
67.30
|
%
|
||
Remaining term (in years)
|
4.34 |
(d) |
Earnings / (Loss) Per Share
|
(e) |
Stock-based Compensation
|
(f)
|
Recent Accounting pronouncements
|
3. |
Business Combination
|
(a)
|
AMCI Acquisition Corp.
|
Recapitalization
|
||||
Cash- AMCI’s trust and cash (net of redemptions)
|
$
|
93,310,599
|
||
Cash – PIPE plus interest
|
65,000,118
|
|||
Less transaction costs and advisory fees paid
|
(17,188,519
|
)
|
||
Less non-cash warrant liability assumed |
(33,116,321 | ) | ||
Net Business Combination and PIPE financing
|
$
|
108,005,877
|
Recapitalization
|
||||
Class A Common A stock of AMCI, outstanding prior to Business Combination
|
9,061,136
|
|||
Less Redemption of AMCI shares
|
(1,606
|
)
|
||
Class B Common Stock of AMCI, outstanding prior to Business Combination
|
5,513,019
|
|||
Shares issued in PIPE
|
6,500,000
|
|||
Business Combination and PIPE financing shares
|
21,072,549
|
|||
Legacy Advent Shares
|
25,033,398
|
|||
Total shares of Common Stock immediately after Business Combination
|
46,105,947
|
(b)
|
UltraCell, LLC
|
Current assets
|
||||
Cash and cash equivalents
|
$
|
77,129
|
||
Other current assets
|
658,332
|
|||
Total current assets
|
$
|
735,461
|
||
Non-current assets
|
9,187
|
|||
Total assets
|
$
|
744,649
|
||
Current liabilities
|
110,179
|
|||
Non-current liabilities
|
-
|
|||
Total liabilities
|
$
|
110,179
|
||
Net assets acquired
|
$
|
634,469
|
Cost of investment
|
$
|
6,000,000
|
||
Net assets value
|
634,469
|
|||
Consideration to be allocated
|
$
|
5,365,531
|
||
Fair value adjustment - New intangibles
|
||||
Trade name "UltraCell"
|
405,931
|
|||
Patented technology
|
4,328,228
|
|||
Total intangibles acquired
|
$
|
4,734,159
|
||
Remaining Goodwill
|
$
|
631,372
|
(c) |
Acquisition
of SerEnergy and FES
|
Current assets
|
||||
Cash and cash equivalents
|
$
|
4,366,802
|
||
Other current assets
|
10,454,864
|
|||
Total current assets
|
$
|
14,821,665
|
||
Non-current assets
|
5,434,180
|
|||
Total assets
|
$
|
20,255,845
|
||
Current liabilities
|
5,818,170
|
|||
Non-current liabilities
|
1,179,618
|
|||
Total liabilities
|
$
|
6,997,788
|
||
Net assets acquired
|
$
|
13,258,057
|
Cost of investment
|
||||
Cash consideration
|
$
|
22,236,111
|
||
Share consideration
|
37,923,860
|
|||
Total cost of investment
|
60,159,971
|
|||
Less: Net assets value
|
13,258,057
|
|||
Original excess purchase price
|
$
|
46,901,914
|
||
Fair value adjustments
|
||||
Real Property
|
76,000
|
|||
New intangibles:
|
||||
Patents
|
17,275,000
|
|||
Process know-how (IPR&D)
|
2,599,000
|
|||
Order backlog
|
247,000
|
|||
Total intangibles acquired
|
$
|
20,121,000
|
||
Deferred tax liability arising from the recognition of intangibles and real property valuation
|
(4,444,000
|
)
|
||
Deferred tax assets on tax losses carried forward
|
1,915,000
|
|||
Remaining Goodwill
|
$
|
29,233,914
|
4. |
Related party disclosures:
|
September 30, 2021
(Unaudited)
|
December 31,
2020
|
|||||||
Due to related parties
|
Unpaid
compensation
cost
|
Unpaid
compensation
cost
|
||||||
Vassilios Gregoriou
|
$
|
-
|
$
|
613,971
|
||||
Emory Sayre De Castro |
-
|
425,528
|
||||||
Christos Kaskavelis | - | 75,160 | ||||||
Charalampos Antoniou | 30,000 | - | ||||||
Total
|
$
|
30,000
|
$
|
1,114,659
|
September 30,
2021
(Unaudited)
|
December 31,
2020
|
|||||||
Due from related parties
|
Prepayment
|
Prepayment
|
||||||
Charalampos Antoniou
|
$
|
-
|
$
|
67,781
|
||||
Total
|
$
|
-
|
$
|
67,781
|
5. |
Inventories:
|
September 30, 2021
(Unaudited)
|
December 31,
2020
|
|||||||
Raw materials and supplies
|
$
|
5,598,574
|
$
|
107,939
|
||||
Total
|
$
|
5,598,574
|
$
|
107,939
|
6. |
Prepaid expenses and other current assets:
|
September 30, 2021
(Unaudited)
|
December 31, 2020
|
|||||||
VAT receivable
|
$
|
826,973
|
$
|
259,831
|
||||
Grants receivable
|
597,155
|
95,064
|
||||||
Other current assets
|
520,007
|
140,126
|
||||||
Prepaid expenses
|
1,822,962
|
1,724
|
||||||
Total
|
$
|
3,767,096
|
$
|
496,745
|
7. |
Property and equipment, net:
|
8.
|
Other non-current assets:
|
9. |
Trade and other payables:
|
September 30, 2021
(Unaudited)
|
December 31,
2020
|
|||||||
Trade payables and other payables
|
$
|
5,522,624
|
$
|
881,394
|
||||
Total
|
$
|
5,522,624
|
$
|
881,394
|
10. |
Other current liabilities:
|
September 30, 2021
(Unaudited)
|
December 31,
2020
|
|||||||
Accrued expenses for legal and consulting fees
|
$
|
1,110,587
|
$
|
814,965
|
||||
Other accruals and short-term payables
|
6,485,032
|
89,414
|
||||||
Total
|
$
|
7,595,619
|
$
|
904,379
|
11. |
Other long-term liabilities:
|
12. |
Private Placement Warrants and Working Capital Warrants:
|
13. |
Stockholders’ Equity / (Deficit):
|
–
|
in whole and not in
part;
|
–
|
at a price of $0.01
per warrant;
|
–
|
upon not less than
30 days’ prior written notice of redemption;
|
–
|
if, and only if, the
reported last sale price of the Company’s common stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption to
the warrant holders; and
|
–
|
if, and only if,
there is a current registration statement in effect with respect to the shares of common stock underlying such warrants.
|
Grant date
|
Number of shares
|
Strike price
|
||||||
June 11, 2021
|
1,959,500
|
$
|
10.36
|
|||||
August 24, 2021
|
230,529
|
$
|
7.62
|
|||||
August 31, 2021
|
457,133
|
$
|
7.40
|
Assumptions
|
||||||||||||
Stock options granted
on June 11, 2021
|
Stock options granted
on August 24, 2021
|
Stock options granted
on August 31, 2021
|
||||||||||
Expected volatility
|
50.0
|
%
|
60.7
|
%
|
65.7
|
%
|
||||||
Risk-free rate
|
1.0
|
%
|
1.0
|
%
|
1.0
|
%
|
||||||
Time to maturity
|
6.075 years
|
6.25 years
|
6.25 years
|
Unvested Shares
|
||||||||
Number of Shares
|
Grant Date
Fair Value
|
|||||||
Unvested as of December 31, 2020
|
-
|
$
|
|
|||||
Granted on June 11, 2021
|
1,959,500
|
$
|
5.04
|
|||||
Granted on August 24, 2021 | 230,529 | $ | 4.32 | |||||
Granted on August 31, 2021 | 457,133 | $ | 4.45 | |||||
Unvested as of September 30, 2021
|
2,647,162
|
|
|
Unvested Restricted Stock Units
|
||||||||
Number of Shares
|
Grant Date
Fair Value
|
|||||||
Unvested as of December 31, 2020
|
-
|
|
|
|||||
Granted on June 11, 2021
|
2,036,716
|
$
|
10.36
|
|||||
Granted on August 24, 2021 | 230,529 | $ | 7.62 | |||||
Granted on August 31, 2021 |
457,122 | $ |
7.40 | |||||
Unvested as of September 30, 2021
|
2,724,367
|
Unvested Restricted Stock
Awards
|
||||||||
Number of Shares
|
Grant Date
Fair Value
|
|||||||
Unvested as of December 31, 2019
|
-
|
$
|
-
|
|||||
Granted
|
2,173,702
|
$
|
0.40
|
|||||
Unvested as of September 30, 2020
|
2,173,702
|
$
|
0.40
|
14.
|
Revenue,
net:
|
Three months ended September 30,
(Unaudited)
|
|
Nine months ended September 30,
(Unaudited)
|
||||||||||||||
2021 | 2020 |
|
2021 |
|
2020 | |||||||||||
Sales of goods
|
$ |
1,673,998 |
$ |
225,412 |
$
|
4,166,754
|
$
|
526,032
|
||||||||
Total revenue from contracts with customers
|
$ |
1,673,998 |
$ |
225,412 |
$
|
4,166,754
|
$
|
526,032
|
15. |
Fair value measurement:
|
16. |
Income Taxes
|
17. |
Commitments and contingencies:
|
17.1
|
Litigation
|
17.2 |
Guarantee letters
|
17.3 |
Operating Leases
|
18. |
Net income / (loss) per share
|
Three months ended September 30,
(Unaudited)
|
Nine months ended September 30,
(Unaudited)
|
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Numerator:
|
||||||||||||||||
Net loss
|
$ | (11,279,722 | ) | $ | (748,816 | ) |
$
|
(11,517,360
|
)
|
$
|
(1,418,037
|
)
|
||||
Denominator:
|
||||||||||||||||
Basic weighted average number of shares
|
48,325,164 |
23,182,817 |
43,982,039
|
21,180,639
|
||||||||||||
Diluted weighted average number of shares
|
48,325,164 |
23,182,817 |
43,982,039
|
21,180,639
|
||||||||||||
Net loss per share:
|
||||||||||||||||
Basic
|
$ | (0.23 | ) | $ | (0.03 | ) |
$
|
(0.26
|
)
|
$
|
(0.07
|
)
|
||||
Diluted
|
$ | (0.23 | ) | $ | (0.03 | ) |
$
|
(0.26
|
)
|
$
|
(0.07
|
)
|
19. |
Subsequent Events
|
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
|
• |
Expand U.S.-based operations to increase capacity for product testing, development projects and associated research and development activities;
|
• |
Expand production facilities to increase and automate assembly and production of fuel cell systems and MEAs;
|
• |
Develop improved MEA and other products for both existing and new markets, such as ultra-light MEAs designed for aviation applications, to remain at the forefront of the fast-developing hydrogen economy;
|
• |
Increase business development and marketing activities;
|
• |
Increase headcount in management and head office functions in order to appropriately manage Advent’s increased operations;
|
• |
Improve its operational, financial and management information systems;
|
• |
Obtain, maintain, expand, and protect its intellectual property portfolio; and
|
• |
Operate as a public company.
|
Three months ended September 30,
(Unaudited)
|
||||||||||||||||
2021
|
2020
|
$ change
|
% change
|
|||||||||||||
Revenue, net
|
$
|
1,673,998
|
$
|
225,412
|
$
|
1,448,586
|
642.6
|
%
|
||||||||
Cost of revenues
|
(1,645,781
|
)
|
(90,477
|
)
|
(1,555,304
|
)
|
1719.0
|
%
|
||||||||
Gross profit / (loss)
|
28,217
|
134,934
|
(106,717
|
)
|
(79.1
|
)%
|
||||||||||
Income from grants
|
507,606
|
16,076
|
491,530
|
3057.6
|
%
|
|||||||||||
Research and development expenses
|
(893,215
|
)
|
(37,640
|
)
|
(855,575
|
)
|
2273.0
|
%
|
||||||||
Administrative and selling expenses
|
(13,040,649
|
)
|
(886,629
|
)
|
(12,154,020
|
)
|
1370.8
|
%
|
||||||||
Amortization of intangibles
|
(309,734
|
)
|
-
|
(309,734
|
)
|
N/A
|
||||||||||
Operating loss
|
(13,707,773
|
)
|
(773,258
|
)
|
(12,934,515
|
)
|
1672.7
|
%
|
||||||||
Finance costs
|
(13,542
|
)
|
(1,712
|
)
|
(11,831
|
)
|
691.1
|
%
|
||||||||
Fair value change of warrant liability
|
2,421,874
|
-
|
2,421,874
|
N/A
|
||||||||||||
Foreign exchange differences, net
|
(15,256
|
)
|
(8,005
|
)
|
(7,251
|
)
|
90.6
|
%
|
||||||||
Other income / (expenses), net
|
(15,960
|
)
|
31,058
|
(47,017
|
)
|
(151.4
|
)%
|
|||||||||
Loss before income tax
|
(11,330,657
|
)
|
(751,917
|
)
|
(10,578,740
|
)
|
1406.9
|
%
|
||||||||
Income tax
|
50,935
|
3,101
|
47,834
|
1542.5
|
%
|
|||||||||||
Net loss
|
$
|
(11,279,722
|
)
|
$
|
(748,816
|
)
|
$
|
(10,530,905
|
)
|
1406.3
|
%
|
|||||
Net loss per share
|
||||||||||||||||
Basic loss per share
|
(0.23
|
)
|
(0.03
|
)
|
(0.20
|
)
|
N/A
|
|||||||||
Basic weighted average number of shares
|
48,325,164
|
23,182,817
|
N/A
|
N/A
|
||||||||||||
Diluted loss per share
|
(0.23
|
)
|
(0.03
|
)
|
(0.20
|
)
|
N/A
|
|||||||||
Diluted weighted average number of shares
|
48,325,164
|
23,182,817
|
N/A
|
N/A
|
Nine months ended September 30,
(Unaudited)
|
||||||||||||||||
2021
|
2020
|
$ change
|
% change
|
|||||||||||||
Revenue, net
|
$
|
4,166,754
|
$
|
526,032
|
$
|
3,640,722
|
692.1
|
%
|
||||||||
Cost of revenues
|
(2,662,476
|
)
|
(374,430
|
)
|
(2,288,046
|
)
|
611.1
|
%
|
||||||||
Gross profit
|
1,504,278
|
151,602
|
1,352,677
|
892.3
|
%
|
|||||||||||
Income from grants
|
631,787
|
159,182
|
472,606
|
296.9
|
%
|
|||||||||||
Research and development expenses
|
(1,561,049
|
)
|
(81,273
|
)
|
(1,479,776
|
)
|
1,820.7
|
%
|
||||||||
Administrative and selling expenses
|
(27,558,242
|
)
|
(1,641,063
|
)
|
(25,917,179
|
)
|
1,579.3
|
%
|
||||||||
Amortization of intangibles
|
(467,447
|
)
|
-
|
(467,447
|
)
|
N/A
|
||||||||||
Operating loss
|
(27,450,672
|
)
|
(1,411,552
|
)
|
(26,039,120
|
)
|
1,844.7
|
%
|
||||||||
Finance costs
|
(26,961
|
)
|
(4,749
|
)
|
(22,212
|
)
|
467.7
|
%
|
||||||||
Fair value change of warrant liability
|
15,833,334
|
-
|
15,833,334
|
N/A
|
||||||||||||
Foreign exchange differences, net
|
(2,141
|
)
|
(26,584
|
)
|
24,443
|
(91.9
|
)%
|
|||||||||
Other income / (expenses), net
|
78,146
|
24,848
|
53,298
|
214.5
|
%
|
|||||||||||
Loss before income tax
|
(11,568,294
|
)
|
(1,418,037
|
)
|
(10,150,257
|
)
|
715.8
|
%
|
||||||||
Income tax
|
50,935
|
-
|
50,935
|
N/A
|
||||||||||||
Net loss
|
$
|
(11,517,359
|
)
|
$
|
(1,418,037
|
)
|
$
|
(10,099,322
|
)
|
712.2
|
%
|
|||||
Net loss per share
|
||||||||||||||||
Basic loss per share
|
(0.26
|
)
|
(0.07
|
)
|
(0.19
|
)
|
N/A
|
|||||||||
Basic weighted average number of shares
|
43,982,039
|
21,180,639
|
N/A
|
N/A
|
||||||||||||
Diluted loss per share
|
(0.26
|
)
|
(0.07
|
)
|
(0.19
|
)
|
N/A
|
|||||||||
Diluted weighted average number of shares
|
43,982,039
|
21,180,639
|
N/A
|
N/A
|
Nine months ended September 30,
(Unaudited)
|
||||||||||||||||
2021
|
2020
|
$ change
|
% change
|
|||||||||||||
Net Cash used in Operating Activities
|
$
|
(24,690,329
|
)
|
$
|
(1,045,004
|
)
|
$
|
(23,645,325
|
)
|
2,262.7
|
%
|
|||||
Cash Flows from Investing Activities:
|
||||||||||||||||
Purchases of property and equipment
|
(2,658,584
|
)
|
(89,123
|
)
|
(2,569,463
|
)
|
2,883.1
|
%
|
||||||||
Advances for the acquisition of property and equipment
|
(1,917,856
|
)
|
-
|
(1,917,856
|
)
|
N/A
|
||||||||||
Acquisition of a subsidiary, net of cash acquired
|
(19,425,378
|
)
|
-
|
(19,425,378
|
)
|
N/A
|
||||||||||
Net Cash used in Investing Activities
|
$
|
(24,001,818
|
)
|
$
|
(89,123
|
)
|
$
|
(23,912,697
|
)
|
26,831.2
|
%
|
|||||
Cash Flows from Financing Activities:
|
||||||||||||||||
Business Combination and PIPE financing, net of issuance costs paid
|
141,120,851
|
-
|
141,120,851
|
N/A
|
||||||||||||
Proceeds of issuance of preferred stock
|
-
|
1,430,005
|
(1,430,005
|
)
|
(100.0
|
)%
|
||||||||||
Proceeds from issuance of non-vested stock awards
|
-
|
21,736
|
(21,736
|
)
|
(100.0
|
)%
|
||||||||||
Repurchase of shares
|
-
|
(69,430
|
)
|
69,430
|
(100.0
|
)%
|
||||||||||
Proceeds of issuance of common stock and paid-in capital from warrants exercise
|
262,177
|
-
|
262,177
|
N/A
|
||||||||||||
State loan proceeds
|
113,377
|
-
|
113,377
|
N/A
|
||||||||||||
Repayment of convertible promissory notes
|
-
|
(500,000
|
)
|
500,000
|
(100.0
|
)%
|
||||||||||
Net Cash provided by Financing Activities
|
$
|
141,496,405
|
$
|
882,311
|
$
|
140,614,094
|
15,937.0
|
%
|
||||||||
Net increase in cash and cash equivalents
|
$
|
92,804,258
|
$
|
(251,815
|
)
|
$
|
93,056,072
|
(36,954.1
|
)%
|
|||||||
Effect of exchange rate changes on cash and cash equivalents
|
(827,624
|
)
|
(17,918
|
)
|
(809,707
|
)
|
4,519.1
|
%
|
||||||||
Cash and cash equivalents at the beginning of the period
|
515,734
|
1,199,015
|
(683,281
|
)
|
(57.0
|
)%
|
||||||||||
Cash and cash equivalents at the end of the period
|
$
|
92,492,367
|
$
|
929,283
|
$
|
91,563,084
|
9,853.1
|
%
|
• |
identify the contract with a customer,
|
• |
identify the performance obligations in the contract,
|
• |
determine the transaction price,
|
• |
allocate the transaction price to performance obligations in the contract, and
|
• |
recognize revenue as the performance obligation is satisfied.
|
EBITDA and Adjusted EBITDA
|
Three months ended September 30,
(Unaudited)
|
Nine months ended September 30,
(Unaudited)
|
||||||||||||||||||||||
(in Millions of US dollars)
|
2021
|
2020
|
$ change
|
2021
|
2020
|
$ change
|
||||||||||||||||||
Net loss
|
$
|
(11.28
|
)
|
$
|
(0.75
|
)
|
(10.53
|
)
|
$
|
(11.52
|
)
|
$
|
(1.42
|
)
|
(10.10
|
)
|
||||||||
Depreciation of property and equipment
|
$
|
0.15
|
$
|
0.01
|
0.15
|
$
|
0.18
|
$
|
0.02
|
0.16
|
||||||||||||||
Amortization of intangibles
|
$
|
0.31
|
$
|
0.00
|
0.31
|
$
|
0.47
|
$
|
0.00
|
0.47
|
||||||||||||||
Finance costs
|
$
|
0.01
|
$
|
0.00
|
0.01
|
$
|
0.03
|
$
|
0.00
|
0.02
|
||||||||||||||
Other income / (expenses), net
|
$
|
0.02
|
$
|
(0.03
|
)
|
0.05
|
$
|
(0.08
|
)
|
$
|
(0.02
|
)
|
(0.05
|
)
|
||||||||||
Foreign exchange differences, net
|
$
|
0.02
|
$
|
0.01
|
0.01
|
$
|
0.00
|
$
|
0.03
|
(0.02
|
)
|
|||||||||||||
EBITDA
|
$
|
(10.77
|
)
|
$
|
(0.76
|
)
|
(10.01
|
)
|
$
|
(10.91
|
)
|
$
|
(1.39
|
)
|
(9.52
|
)
|
||||||||
Net change in warrant liability
|
$
|
(2.42
|
)
|
$
|
-
|
(2.42
|
)
|
$
|
(15.83
|
)
|
$
|
-
|
(15.83
|
)
|
||||||||||
One-Time Transaction Related Expenses (1)
|
$
|
-
|
$
|
-
|
-
|
$
|
5.87
|
$
|
-
|
5.87
|
||||||||||||||
One-Time Transaction Related Expenses (2)
|
$
|
0.89
|
$
|
-
|
0.89
|
$
|
0.89
|
$
|
-
|
0.89
|
||||||||||||||
Executive severance (3)
|
$
|
2.44
|
$
|
-
|
2.44
|
$
|
2.44
|
$
|
-
|
2.44
|
||||||||||||||
Adjusted EBITDA
|
$
|
(9.86
|
)
|
$
|
(0.76
|
)
|
(9.10
|
)
|
$
|
(17.54
|
)
|
$
|
(1.39
|
)
|
(16.15
|
)
|
Adjusted Net Loss
|
Three months ended September 30,
(Unaudited)
|
Nine months ended September 30,
(Unaudited)
|
||||||||||||||||||||||
(in Millions of US dollars)
|
2021
|
2020
|
$ change
|
2021
|
2020
|
$ change
|
||||||||||||||||||
Net loss
|
$
|
(11.28
|
)
|
$
|
(0.75
|
)
|
(10.53
|
)
|
$
|
(11.52
|
)
|
$
|
(1.42
|
)
|
(10.10
|
)
|
||||||||
Net change in warrant liability
|
$
|
(2.42
|
)
|
$
|
-
|
(2.42
|
)
|
$
|
(15.83
|
)
|
$
|
-
|
(15.83
|
)
|
||||||||||
One-Time Transaction Related Expenses (1)
|
$
|
-
|
$
|
-
|
-
|
$
|
5.87
|
$
|
-
|
5.87
|
||||||||||||||
One-Time Transaction Related Expenses (2)
|
$
|
0.89
|
$
|
-
|
0.89
|
0.89
|
$
|
-
|
0.89
|
|||||||||||||||
Executive severance (3)
|
$
|
2.44
|
$
|
-
|
2.44
|
$
|
2.44
|
$
|
-
|
2.44
|
||||||||||||||
Adjusted Net Loss
|
$
|
(10.37
|
)
|
$
|
(0.75
|
)
|
(9.62
|
)
|
$
|
(18.15
|
)
|
$
|
(1.42
|
)
|
(16.73
|
)
|
Item 3. |
Quantitative and Qualitative Disclosures about Market Risk.
|
Item 1. |
Legal Proceedings.
|
Item 1A. |
Risk Factors.
|
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds.
|
Item 3. |
Exhibits
|
Exhibit
Number
|
Description
|
|
31.1*
|
Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002
|
|
31.2*
|
Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002
|
|
32.1†
|
Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
32.2†
|
Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
101
|
The following materials from the Quarterly Report on Form 10-Q of Advent Technologies Holdings, Inc. formatted in Inline XBRL:
|
|
104
|
The cover page from the Quarterly Report on Form 10-Q of Advent Technologies Holdings, Inc. for the quarter ended September 30, 2021 formatted in Inline XBRL and included as Exhibit 101
|
* |
Filed herewith
|
†
|
This certification will not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference
into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.
|
Date: November 15, 2021
|
ADVENT TECHNOLOGIES HOLDINGS, INC.
|
|
By:
|
/s/ Kevin Brackman
|
|
Kevin Brackman
|
||
Chief Financial Officer
|
||
(Authorized Officer; Principal Financial and Accounting Officer)
|
Delaware
|
001-38742
|
83-0982969
|
||
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
Common Stock, par value $0.0001 per share
|
ADN
|
The Nasdaq Stock Market LLC
|
||
Warrants to purchase one share of common stock, each at an exercise price of $11.50
|
ADNWW
|
The Nasdaq Stock Market LLC
|
Item 2.01 |
Financial Statements and Exhibits.
|
Item 8.01 |
Other Events.
|
• |
has, in the absence of a waiver from the SEC, rendered us ineligible for 12 months to use the SEC’s short-form registration statement on Form S-3 to register the issuance of our securities for any
capital raising activities;
|
• |
will make, in the absence of a waiver from the SEC, during the period that we are ineligible to use S-3, our existing S-1 registration statements more expensive and time consuming to maintain; and
|
• |
could, depending on when the financial statements of the Target Companies become available and we file them along with other required financial information regarding our acquisition of the Target
Companies, have other material and adverse consequences that are summarized below.
|
ADVENT TECHNOLOGIES HOLDINGS, INC.
|
|||
By:
|
/s/ Kevin Brackman
|
||
Dated: November 15, 2021
|
Name:
|
Kevin Brackman
|
|
Title:
|
Chief Financial Officer
|